Indication, surgical procedure and clinical performance of the new active osseointegrated implant system, das OsiaTM system, a retrospective Study

Objective The Osia system is the most recent active transcutaneous osseointegrated device, which was introduced in the United States in 2019. The System utilizes the same BI300 osseointegrated implant as other Cochlear devices with the OSIA200 implant fixated to the BI300 screw. This Piezo Power transducer is made of piezoelectric layers that produce mechanical vibration when an electric voltage is applied by an external sound processor. This System is indicated for patients with conductive hearing loss or mixed hearing loss with bone conduction PTA thresholds of 55 dB or better, and in single-sided deafness. We conducted a monocentric retrospective Study in the University Hospital in Lübeck to investigate the indications, the surgical procedure and the clinical performance of the Osia System and its impact on the health status.

Methods In 2021 and 2022, 7 Osia200 implants were implanted in 5 adults (4: CHL; 3: MHL); two patients received bilateral implants.

Results The new Osia system provided a significant functional audiological gain with an enhanced speech recognition in quiet in all subjects in the follow-up analysis. There was no noticeable alteration of the bone conduction thresholds postoperatively. The surgery was relatively straightforward without major intra- oder postoperative complications. All patients confirmed a hearing improvement from the day the sound processor was activated.

Conclusion The Osia System is an effective and safe method for aural rehabilitation for patients with conductive and mixed hearing loss or in single sided deafness.

Publikationsverlauf

Artikel online veröffentlicht:
12. Mai 2023